Literature DB >> 16003167

Flavanols for cardiovascular health: the science behind the sweetness.

Naomi D L Fisher1, Norman K Hollenberg.   

Abstract

PURPOSE OF REVIEW: Cardiovascular benefits for cocoa are being claimed in the scientific literature with growing intensity. To date, excitement over the potential health benefits of flavonoids has been driven mostly by epidemiological studies of tea and red wine, but raw cocoa contains specific flavonoids in concentrations far exceeding those from most other sources. Early evidence supports cocoa's enhancement of endothelial function via improvement of nitric oxide synthesis. However, many new studies have brought more confusion than clarity to the enterprise. This review provides guidelines for legitimate research in this promising field. TOPICS OF DISCUSSION: Evidence generated from epidemiological studies, linking an increase in flavonoid ingestion to a reduction in cardiovascular events, is less convincing than data from controlled clinical trials. Whereas a few trials have shown evidence for an enhancement of endothelial function, inhibition of platelet adhesion and low-density lipoprotein oxidation, many studies have ignored scientific principles. Tremendous variability in cocoa processing, flavonoid content, measurement and dosing threatens the field. Valid research depends upon the precise identification and measurement of compounds of interest, which are probably the flavanols catechin and epicatechin, their oligomers and metabolites. These measures depend upon reliable methods of separation and quantification. Whether the monomers, dimers or larger flavanol oligomers, or their metabolites, are responsible for biological efficacy remains to be determined. Final questions surround bioavailability and dosing frequency.
CONCLUSIONS: Evidence is mounting to support cardiovascular health benefits from the consumption of flavanol-rich cocoa. This review hopes to illuminate sound scientific principles by which future research in the field can be guided.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16003167     DOI: 10.1097/01.hjh.0000174605.34027.9d

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion.

Authors:  Katrina Go Yamazaki; Pam R Taub; Maraliz Barraza-Hidalgo; Maria M Rivas; Alexander C Zambon; Guillermo Ceballos; Francisco J Villarreal
Journal:  J Am Coll Cardiol       Date:  2010-06-22       Impact factor: 24.094

2.  Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy.

Authors:  Katsuyuki Tanabe; Yoshifuru Tamura; Miguel A Lanaspa; Makoto Miyazaki; Norihiko Suzuki; Waichi Sato; Yohei Maeshima; George F Schreiner; Francisco J Villarreal; Richard J Johnson; Takahiko Nakagawa
Journal:  Am J Physiol Renal Physiol       Date:  2012-08-29

3.  Short- and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury.

Authors:  Katrina Go Yamazaki; Diego Romero-Perez; Maraliz Barraza-Hidalgo; Michelle Cruz; Maria Rivas; Brenda Cortez-Gomez; Guillermo Ceballos; Francisco Villarreal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

4.  Sulfation of dietary flavonoids by human sulfotransferases.

Authors:  C Huang; Y Chen; T Zhou; G Chen
Journal:  Xenobiotica       Date:  2009-04       Impact factor: 1.908

5.  Stimulatory effects of the flavanol (-)-epicatechin on cardiac angiogenesis: additive effects with exercise.

Authors:  Israel Ramirez-Sanchez; Leonardo Nogueira; Aldo Moreno; Ann Murphy; Pam Taub; Guy Perkins; Guillermo M Ceballos; Michael Hogan; Moh Malek; Francisco Villarreal
Journal:  J Cardiovasc Pharmacol       Date:  2012-11       Impact factor: 3.105

6.  Does flavanol intake influence mortality from nitric oxide-dependent processes? Ischemic heart disease, stroke, diabetes mellitus, and cancer in Panama.

Authors:  Vicente Bayard; Fermina Chamorro; Jorge Motta; Norman K Hollenberg
Journal:  Int J Med Sci       Date:  2007-01-27       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.